DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Novartis
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Brown University
Mayo Clinic
University of Kentucky
Eli Lilly and Company
University of California, Davis
University of Cincinnati
University of Michigan Rogel Cancer Center
Hoffmann-La Roche
New Mexico Cancer Research Alliance
Seagen Inc.
National University Hospital, Singapore
University of Chicago
Novartis
Dana-Farber Cancer Institute
Stanford University
Vanderbilt-Ingram Cancer Center